What Is Thymalin?
Thymalin is a polypeptide preparation derived from bovine thymus gland through standardized extraction. Unlike the fully synthetic thymic bioregulators (Thymogen, Vladonix), Thymalin contains a mixture of naturally occurring thymic peptides including fractions with thymosin-like, thymopentin-like, and thymulin-like activities. It has been used clinically in Russia and Eastern Europe for immune deficiency states and is one of the most extensively clinically evaluated thymic preparations. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Thymic Involution and Aging
The thymus reaches peak activity in childhood and undergoes progressive involution from puberty onward, losing 3% of its functional tissue per year. By age 65, the thymus has lost approximately 95% of its T-cell generating capacity. This thymic involution is the primary driver of immunosenescence — the age-related decline in immune function increasing infection susceptibility, reducing vaccine efficacy, and possibly increasing cancer risk.
Research and Clinical Applications
Thymalin has been studied and used clinically for secondary immunodeficiency (post-chemotherapy, post-infection), primary immunodeficiency states, recurrent infections in the elderly, and anti-aging protocols. Long-term studies by Khavinson's group in elderly subjects documented reduced cancer incidence, improved immune parameters, and lower cardiovascular mortality over 6–8 year follow-up periods in subjects receiving periodic bioregulator courses including Thymalin.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19
Khavinson VKh, Kuznik BI, Trofimova SV, Lukyanov SA, Rutkovskaya VN, 2021, Stem Cell Reviews and Reports - The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity
Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM, 2021, Biology Bulletin Reviews - Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG, 2003, Neuroendocrinology Letters - Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells
Khavinson VK, Linkova NS, Kvetnoy IM, et al., 2020, Bulletin of Experimental Biology and Medicine - The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19
Linkova N, Khavinson V, Diatlova A, et al., 2023, International Journal of Molecular Sciences - Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK, et al., 2022, International Journal of Molecular Sciences - Thymic peptides for treatment of cancer patients
Wolf E, Milazzo S, Boehm K, Zwahlen M, Horneber M, 2011, Cochrane Database of Systematic Reviews - Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK, 2022, Int J Mol Sci - Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells
Khavinson VK, Linkova NS, Kvetnoy IM, 2020, Bull Exp Biol Med - [Geroprotective effect of thymalin and epithalamin]
Khavinson VKh, Morozov VG, 2002, Adv Gerontol - The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19
Linkova N, Khavinson V, Diatlova A, 2023, Int J Mol Sci - [Influence of peptides from pineal gland on thymus function at aging]
Lin'kova NS, Poliakova VO, Trofimov AV, 2010, Adv Gerontol - Khavinson development attribution. Avolio et al. Int J Mol Sci. 2022;23(7):3607. Khavinson peptide attribution.
Thymalin is a polypeptide preparation derived from bovine thymus gland through standardized extraction. Unlike the fully synthetic thymic bioregulators (Thymogen, Vladonix), Thymalin contains a mixture of naturally occurring thymic peptides including fractions with thymosin-like, thymopentin-like, and thymulin-like activities. It has been used clinically in Russia and Eastern Europe for immune deficiency states and is one of the most extensively clinically evaluated thymic preparations.